Cereno Scientific strengthens patent protection for Phase II drug candidate CS1 across two patent families
Cereno Scientific today announced that the intellectual property rights (IPR) for drug candidate CS1 have been expanded in two different patent families. The patent granted in Canada belongs to the company’s first patent family, and the patent granted in Russia belongs to the company’s second patent family. This is a result of Cereno’s continuous work in securing IPR for its assets to strengthen the commercial positioning.
“Working to continuously strengthen our IPR around our drug candidates and technology is an important part of our strategy aimed at optimally positioning Cereno for commercial success,” says Sten R. Sörensen, CEO at Cereno Scientific.
Jonas Faijerson Säljö, Chief Intellectual Property Officer at Cereno Scientific, says “ Securing IPR is crucial within drug development and, thus, our strategy and activities are constantly evaluated as we advance in our clinical development.”
In Canada, the patent granted belongs to Cereno’s first patent family and is titled “Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors.” The patent number is CA2866333. This patent will be valid through 2032, with the possibility of a patent extension of additional two years maximum according to Canadian regulations.
The patent granted in the Russian market is part of Cereno’s second patent family in relation to drug candidate CS1. The patent is titled “Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation,” with patent number RU2732761. The Russian patent will be valid through 2035, with the possibility of a patent extension of additional five years maximum.
For further information, please contact:
Daniel Brodén, CFO
Tel: +46 768 66 77 87
Email: info@cerenoscientific.com
www.cerenoscientific.com/
About Cereno Scientific AB
Cereno Scientific is a leading clinical stage biotech company within cardiovascular epigenetic modulation. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. A clinical phase II study program for CS1 in PAH is expected to be initiated in mid-2021 under its US FDA granted orphan drug designation (ODD) status. In addition, Cereno has a preclinical HDAC inhibitor development program targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has an office in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.